NCT00496756 2023-10-26
Sorafenib in Treating Patients With Metastatic or Unresectable Kidney Cancer
University of Nebraska
Phase 2 Terminated
Clinical Trials
52 trialsNCT02575339 2022-07-26
MLN0128 Compared to Sorafenib in Advanced or Metastatic Hepatocellular Carcinoma
Big Ten Cancer Research Consortium
Phase 1/2 Terminated
NCT04326439 2022-06-15
AflacLL1901 (CHOA-AML)
Emory University
Phase 2 Terminated
NCT01620216 2021-11-04
Targeted Therapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myelogenous Leukemia
OHSU Knight Cancer Institute
Phase 2 Terminated
NCT01141478 2021-10-15
HCC
Loma Linda University
Phase NA Terminated
NCT03630120 2021-07-14
Adaptive Tyrosine Kinase Inhibitor (TKI) Therapy In Patients With Thyroid Cancer
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Terminated
NCT01032850 2021-06-02
Sorafenib With Capecitabine for Patients With Measurable Hepatocellular Carcinoma
New Mexico Cancer Research Alliance
Phase 2 Terminated
NCT01887717 2021-04-21
YES-P
Boston Scientific Corporation
Phase 3 Terminated
NCT02460991 2021-02-12
SOLACE
Boston Scientific Corporation
Phase 3 Terminated
NCT00622466 2020-10-19
Sorafenib and Paclitaxel in Treating Patients With Metastatic Breast Cancer
University of Texas Southwestern Medical Center
Phase 2 Terminated
NCT00880542 2020-08-10
Sorafenib and Ifosfamide in Treating Patients With High-Grade Soft Tissue Sarcoma or Bone Sarcoma That Can Be Removed by Surgery
Jonsson Comprehensive Cancer Center
Phase 2 Terminated
NCT02624700 2020-07-14
2nd Line Treatment With Pemetrexed and Sorafenib for Recurrent or Metastatic Triple Negative Breast Cancer
Virginia Commonwealth University
Phase 2 Terminated
NCT00687674 2019-08-20
Sorafenib, Lenalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma
Mayo Clinic
Phase 1 Terminated
NCT00727532 2019-05-03
Sorafenib in Treating Patients With Locally Advanced or Metastatic Kidney Cancer
Northwestern University
Phase NA Terminated
NCT00754923 2019-03-06
Sorafenib in Treating Non-Smokers or Former Light Smokers With Relapsed or Refractory Stage IIIB or Stage IV Non-Small Cell Lung Cancer
Ohio State University Comprehensive Cancer Center
Phase 2 Terminated
NCT00924807 2018-12-11
Safety Study of Sorafenib With Androgen Deprivation and Radiotherapy to Treat Prostate Cancer
Beth Israel Medical Center
Phase 1/2 Terminated
NCT00126659 2018-11-20
Sorafenib in Treating Patients Who Are Undergoing Surgery for Metastatic Kidney Cancer
National Cancer Institute (NCI)
Phase 2 Terminated
NCT02560012 2018-10-12
Personalized Targeted Inhibitors Treatment in Renal Cell Cancer
The University of Texas Health Science Center, Houston
Phase 2 Terminated
NCT00722072 2018-02-26
Sorafenib and Fulvestrant in Treating Patients With Locally Advanced or Metastatic Breast Cancer That Did Not Respond to Aromatase Inhibitor Therapy
OHSU Knight Cancer Institute
Phase 2 Terminated
NCT00632541 2018-02-14
A Phase II Study of Bevacizumab + Sorafenib in Metastatic Breast Cancer
Hoosier Cancer Research Network
Phase 2 Terminated
NCT00126568 2018-01-19
Sorafenib in Treating Patients With Advanced Anaplastic Thyroid Cancer
National Cancer Institute (NCI)
Phase 2 Terminated
NCT00955721 2018-01-03
A Study of Combination of Gemcitabine, Oxaliplatin (GEMOX)-Sorafenib in Patients With Advanced Biliary Tract Cancer
University of Miami
Phase 1/2 Terminated
NCT01334710 2017-11-21
A Phase II Trial of OSI-906 and Sorafenib in Advanced Hepatocellular Cancer
Emory University
Phase 2 Terminated
NCT00801801 2017-05-17
Study of Low Dose Chemotherapy Plus Sorafenib as Initial Therapy for Patients With Advanced Non-Squamous Cell NSCLC
University of Alabama at Birmingham
Phase 2 Terminated
NCT01005875 2017-05-10
RAD 0901
University of Alabama at Birmingham
Phase NA Terminated
NCT01849588 2017-04-19
HCV-RNA Kinetics During Sorafenib for Hepatocellular Carcinoma (HCC)
Massachusetts General Hospital
Phase 4 Terminated
NCT00576056 2017-02-15
Effectiveness and Safety Study of TACE Plus Oral Sorafenib for Unresectable HCC
University of Pittsburgh
Phase 2 Terminated
NCT01194869 2016-10-18
Preoperative Trial of Sorafenib in Combination With Cisplatin Followed by Paclitaxel for Early Stage Breast Cancer
Emory University
Phase 2 Terminated
NCT00417248 2016-07-25
Cisplatin/Etoposide/Radiotherapy Followed by Consolidation Sorafenib for Inoperable Stage III Non-Small Cell Lung Cancer
Hoosier Cancer Research Network
Phase 1/2 Terminated
NCT00510289 2016-04-19
Sorafenib in Myelodysplastic Syndrome
Duke University
Phase 2 Terminated
NCT00526799 2016-03-03
Sorafenib + Topotecan for Platinum-Resistant Recurrent Ovarian Cancer
Hoosier Cancer Research Network
Phase 1/2 Terminated
NCT00522301 2016-02-29
Sorafenib in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer in at Least the Second Remission
Memorial Sloan Kettering Cancer Center
Phase 2 Terminated
NCT00573755 2016-02-05
Sorafenib and Letrozole, Anastrozole, or Exemestane in Treating Postmenopausal Women With Estrogen Receptor-Positive and/or Progesterone Receptor-Positive Metastatic Breast Cancer
Mayo Clinic
Phase 2 Terminated
NCT01510756 2016-01-21
Sorafenib for the Treatment of Chronic Lymphocytic Leukemia (CLL)
University of California, San Diego
Phase 2 Terminated
NCT00673361 2016-01-13
Pilot Trial of "Chemo-Switch" Regimen to Treat Advanced Melanoma
Duke University
Phase 2 Terminated
NCT00714948 2015-11-16
Gemcitabine and Split-dose Cisplatin (GC) Plus Sorafenib in Chemotherapy-naïve Patients With Locally Advanced or Metastatic Urothelial Carcinoma
Memorial Sloan Kettering Cancer Center
Phase 2 Terminated
NCT01100242 2015-09-17
Velcade and Sorafenib in Unresected or Metastatic Renal Cell Carcinoma
New Mexico Cancer Research Alliance
Phase 2 Terminated
NCT00589550 2015-06-08
PEG-Interferon Alfa-2b and Sorafenib in Treating Patients With Unresectable or Metastatic Kidney Cancer
Ohio State University Comprehensive Cancer Center
Phase 1 Terminated
NCT00525161 2015-01-26
Study Adding Multikinase Inhibitor Sorafenib to Existing Endocrine Therapy in Patients With Advanced Breast Cancer
University of Kentucky
Phase 2 Terminated
NCT00678288 2014-12-11
A Study to Assess Sorafenib Alone and in Combination With Low-Dose Interferon Following Unsuccessful Treatment With Sunitinib in Patients With Advanced Renal Cell Cancer.
Bayer
Phase 2 Terminated
NCT00726986 2014-11-19
Sorafenib, Cisplatin, and Etoposide in Treating Patients With Extensive-Stage Small Cell Lung Cancer
Case Comprehensive Cancer Center
Phase 2 Terminated
NCT00300885 2014-11-04
A Randomized Controlled Trial Comparing Safety and Efficacy of Carboplatin and Paclitaxel Plus or Minus Sorafenib (BAY 43-9006) in Chemonaive Patients With Stage IIIB-IV Non-Small Cell Lung Cancer (NSCLC)
Bayer
Phase 3 Terminated
NCT00112905 2014-05-30
Sorafenib in Treating Patients With Regional or Metastatic Cancer of the Urothelium
National Cancer Institute (NCI)
Phase 2 Terminated
NCT00303966 2014-05-07
Sorafenib in Treating Patients With Relapsed Chronic Lymphocytic Leukemia
National Cancer Institute (NCI)
Phase 2 Terminated
NCT00619242 2014-03-12
Barrett's
University of Chicago
Phase NA Terminated
NCT00558636 2013-12-27
A Trial Comparing Safety and Efficacy of Carboplatin and Paclitaxel Plus or Minus Sorafenib (BAY43-9006) in Chemonaive Patients With Stage IIIB-IV Non-Small Cell Lung Cancer (NSCLC)
Bayer
Phase 3 Terminated
NCT00964743 2013-09-09
Depocyt® With Sorafenib in Neoplastic Meningitis
H. Lee Moffitt Cancer Center and Research Institute
Phase NA Terminated
NCT00862082 2013-08-23
Randomized Phase 1/2 Open-Label Trial of PR104 and Sorafenib in Patients With Advanced Hepatocellular Carcinoma (HCC)
Proacta, Incorporated
Phase 1/2 Terminated
NCT00557830 2013-07-18
Randomized Study of Sorafenib Dose Escalation in Patients With Previously Untreated Metastatic Renal Cell Carcinoma
Accelerated Community Oncology Research Network
Phase 2 Terminated
NCT00699374 2013-01-14
Study Of Sunitinib Malate Versus Sorafenib In Patients With Inoperable Liver Cancer
Pfizer
Phase 3 Terminated